T4 - General Session: Facing the Challenges: Managing Hyperkalemia in Heart Failure Patients While Maintaining RAASi Therapy Supported by an Independent Educational Grant from AstraZeneca
11:15 AM - 12:15 PM East Coast USA Time
T4 - General Session: Facing the Challenges: Managing Hyperkalemia in Heart Failure Patients While Maintaining RAASi Therapy Supported by an Independent Educational Grant from AstraZeneca
T13 - Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience Supported by an Educational Grant from Alnylam Pharmaceuticals, Inc.
4:00 PM - 5:00 PM East Coast USA Time
T13 - Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience Supported by an Educational Grant from Alnylam Pharmaceuticals, Inc.
P008 Maintenance or Improvement of Functional Capacity, Health Status, and Quality of Life with Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Data from the HELIOS-B Study
P014 Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRA-201 (Non-CE)
P019 Referral to a Heart Failure Clinic Substantially Increases the Use of Angiotensin Receptor Neprilysin Inhibitor (ARNi) and Sodium-glucose cotransporter-2 Inhibitor (SGLT2i) in Heart Failure Patients.
P020 The Impact Of Increased Early Utilization Of Angiotensin Receptor Neprilysin Inhibitor (ARNi) And Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) In New Onset And Chronic HFrEF
P027 Effects of Targeted Nursing Medication Education on Heart Failure (HF) Patient Adherence and 30-Day Hospitalizations in a Small Community Based HF Clinic
P021 Nurse Practitioners in Advanced Heart Failure Outreach Clinics strengthen partnerships with community providers, increase access to advanced therapies, and improve outcomes for patients in rural communities
F2 - General Session: Iron Deficiency in Heart Failure: Best Practices in Diagnosis, Treatment, and Implementation of Iron Supplementation Supported by an Independent Educational Grant from American Regent
9:30 AM - 10:30 AM East Coast USA Time
F2 - General Session: Iron Deficiency in Heart Failure: Best Practices in Diagnosis, Treatment, and Implementation of Iron Supplementation Supported by an Independent Educational Grant from American Regent
F6 - Industry Supported CE Symposium: Roadmap from GDMT to Device Therapy: Overview of CCM Therapy Supported by an Independent Educational Grant from Impulse Dynamics
12:00 PM - 1:15 PM East Coast USA Time
F6 - Industry Supported CE Symposium: Roadmap from GDMT to Device Therapy: Overview of CCM Therapy Supported by an Independent Educational Grant from Impulse Dynamics
Location: Room 201-202
Moderator: Chris Bell, ACNP – Cardiology Associates of North Mississippi
Industry Supported Dinner Symposium Heartfelt Journey Into the Diagnosis of NYHA Class II-III Obstructive HCM and Management With Cardiac Myosin Inhibition Sponsored by Bristol Myers Squibb
5:30 PM - 7:00 PM East Coast USA Time
Industry Supported Dinner Symposium Heartfelt Journey Into the Diagnosis of NYHA Class II-III Obstructive HCM and Management With Cardiac Myosin Inhibition Sponsored by Bristol Myers Squibb
Saturday, June 14, 2025
7:00 AM - 2:00 PM East Coast USA Time
Registration Hours
7:00 AM - 2:00 PM East Coast USA Time
Registration Hours
Location: Exhibit Hall A Foyer
7:15 AM - 8:30 AM East Coast USA Time
Industry Supported Breakfast Symposium: Seeing the Unseen: Revealing Clues to Identify Obstructive Hypertrophic Cardiomyopathy (oHCM) Sponsored by Cytokinetics
7:15 AM - 8:30 AM East Coast USA Time
Industry Supported Breakfast Symposium: Seeing the Unseen: Revealing Clues to Identify Obstructive Hypertrophic Cardiomyopathy (oHCM) Sponsored by Cytokinetics
Industry Supported Lunch Symposium: On the Front Line: The Heart Failure Nurse’s Role in the Screening and Management of ATTR Cardiac Amyloidosis Sponsored by Pfizer
12:30 PM - 2:00 PM East Coast USA Time
Industry Supported Lunch Symposium: On the Front Line: The Heart Failure Nurse’s Role in the Screening and Management of ATTR Cardiac Amyloidosis Sponsored by Pfizer